Kristen Kluska
Stock Analyst at Cantor Fitzgerald
(4.39)
# 384
Out of 4,667 analysts
199
Total ratings
41.57%
Success rate
31.91%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kristen Kluska
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDXS Codexis | Reiterates: Overweight | $11 | $4.51 | +143.90% | 5 | Nov 15, 2024 | |
| TSHA Taysha Gene Therapies | Reiterates: Overweight | $7 | $2.04 | +243.98% | 15 | Nov 14, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Overweight | $25 → $30 | $17.53 | +71.10% | 4 | Nov 14, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Overweight | $20 → $21 | $9.49 | +121.40% | 6 | Nov 7, 2024 | |
| SRPT Sarepta Therapeutics | Upgrades: Overweight | $152 → $167 | $110.07 | +51.72% | 13 | Nov 7, 2024 | |
| QURE uniQure | Reiterates: Overweight | $28 | $5.69 | +392.52% | 8 | Nov 6, 2024 | |
| RARE Ultragenyx Pharmaceutical | Reiterates: Overweight | $116 | $46.74 | +148.18% | 16 | Nov 6, 2024 | |
| ABEO Abeona Therapeutics | Reiterates: Overweight | $18 | $5.89 | +205.60% | 8 | Oct 29, 2024 | |
| IRON Disc Medicine | Reiterates: Overweight | $85 | $63.65 | +33.55% | 7 | Oct 15, 2024 | |
| MREO Mereo BioPharma Group | Reiterates: Overweight | $7 | $3.59 | +95.26% | 9 | Oct 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $14 | $4.29 | +226.72% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $15 | $24.01 | -37.53% | 5 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $53.91 | +24.28% | 5 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $64 | $42.36 | +51.09% | 16 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $13 | $4.42 | +194.12% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $29 | $7.97 | +263.86% | 12 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $67 | $26.89 | +149.16% | 13 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $20 | $21.29 | -6.06% | 8 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.05 | - | 3 | Sep 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $0.34 | +1,384.12% | 3 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $21 | $1.40 | +1,405.38% | 3 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $0.61 | +891.74% | 3 | Feb 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $90 → $20 | $5.10 | +292.54% | 2 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $23 | $2.25 | +922.22% | 2 | Aug 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $18 | $0.21 | +8,508.32% | 1 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $44 → $41 | $0.88 | +4,585.71% | 2 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $400 | $5.84 | +6,744.74% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,250 → $85 | $2.29 | +3,611.79% | 3 | Oct 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $0.70 | +9,900.00% | 1 | Feb 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $45 | $1.60 | +2,712.68% | 1 | May 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $11 | $0.94 | +1,072.83% | 3 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $3.00 | +1,900.00% | 2 | Mar 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $1.53 | +5,782.35% | 1 | Dec 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $10,620 → $2,520 | $2.86 | +87,925.71% | 2 | Jan 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $160 | $0.51 | +31,520.55% | 1 | Jan 9, 2020 |
Codexis
Nov 15, 2024
Reiterates: Overweight
Price Target: $11
Current: $4.51
Upside: +143.90%
Taysha Gene Therapies
Nov 14, 2024
Reiterates: Overweight
Price Target: $7
Current: $2.04
Upside: +243.98%
Capricor Therapeutics
Nov 14, 2024
Maintains: Overweight
Price Target: $25 → $30
Current: $17.53
Upside: +71.10%
Amicus Therapeutics
Nov 7, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $9.49
Upside: +121.40%
Sarepta Therapeutics
Nov 7, 2024
Upgrades: Overweight
Price Target: $152 → $167
Current: $110.07
Upside: +51.72%
uniQure
Nov 6, 2024
Reiterates: Overweight
Price Target: $28
Current: $5.69
Upside: +392.52%
Ultragenyx Pharmaceutical
Nov 6, 2024
Reiterates: Overweight
Price Target: $116
Current: $46.74
Upside: +148.18%
Abeona Therapeutics
Oct 29, 2024
Reiterates: Overweight
Price Target: $18
Current: $5.89
Upside: +205.60%
Disc Medicine
Oct 15, 2024
Reiterates: Overweight
Price Target: $85
Current: $63.65
Upside: +33.55%
Mereo BioPharma Group
Oct 1, 2024
Reiterates: Overweight
Price Target: $7
Current: $3.59
Upside: +95.26%
Sep 20, 2024
Reiterates: Overweight
Price Target: $14
Current: $4.29
Upside: +226.72%
Sep 20, 2024
Reiterates: Neutral
Price Target: $15
Current: $24.01
Upside: -37.53%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $53.91
Upside: +24.28%
Sep 20, 2024
Reiterates: Overweight
Price Target: $64
Current: $42.36
Upside: +51.09%
Sep 20, 2024
Reiterates: Overweight
Price Target: $13
Current: $4.42
Upside: +194.12%
Sep 20, 2024
Reiterates: Overweight
Price Target: $29
Current: $7.97
Upside: +263.86%
Sep 20, 2024
Reiterates: Overweight
Price Target: $67
Current: $26.89
Upside: +149.16%
Sep 20, 2024
Reiterates: Overweight
Price Target: $20
Current: $21.29
Upside: -6.06%
Sep 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $3.05
Upside: -
May 31, 2024
Reiterates: Overweight
Price Target: $5
Current: $0.34
Upside: +1,384.12%
Apr 30, 2024
Reiterates: Overweight
Price Target: $21
Current: $1.40
Upside: +1,405.38%
Feb 5, 2024
Reiterates: Overweight
Price Target: $6
Current: $0.61
Upside: +891.74%
Aug 30, 2023
Downgrades: Neutral
Price Target: $90 → $20
Current: $5.10
Upside: +292.54%
Aug 29, 2023
Reiterates: Overweight
Price Target: $23
Current: $2.25
Upside: +922.22%
Aug 24, 2023
Reiterates: Overweight
Price Target: $18
Current: $0.21
Upside: +8,508.32%
Aug 10, 2023
Maintains: Overweight
Price Target: $44 → $41
Current: $0.88
Upside: +4,585.71%
Mar 17, 2023
Initiates: Overweight
Price Target: $400
Current: $5.84
Upside: +6,744.74%
Oct 7, 2022
Downgrades: Neutral
Price Target: $1,250 → $85
Current: $2.29
Upside: +3,611.79%
Feb 28, 2022
Initiates: Overweight
Price Target: $70
Current: $0.70
Upside: +9,900.00%
May 26, 2021
Initiates: Overweight
Price Target: $45
Current: $1.60
Upside: +2,712.68%
May 7, 2021
Downgrades: Neutral
Price Target: $15 → $11
Current: $0.94
Upside: +1,072.83%
Mar 19, 2021
Initiates: Overweight
Price Target: $60
Current: $3.00
Upside: +1,900.00%
Dec 1, 2020
Initiates: Overweight
Price Target: $90
Current: $1.53
Upside: +5,782.35%
Jan 30, 2020
Assumes: Overweight
Price Target: $10,620 → $2,520
Current: $2.86
Upside: +87,925.71%
Jan 9, 2020
Initiates: Overweight
Price Target: $160
Current: $0.51
Upside: +31,520.55%